-
The Belfer Center is part of Dana-Farber Cancer Institute. We advance discoveries and therapies to translate today’s science into tomorrow’s treatments.
-
We accelerate discovery and development of the next generation of targeted and immune-based therapies
-
We integrate academic and industrial research to drive clinical trials and improve patients’ lives
The Belfer Center is part of Dana-Farber Cancer Institute. We advance discoveries and therapies to translate today’s science into tomorrow’s treatments.
Spotlight
Twitter feed
The following #ASCO22 health & safety protocols are in place:
✅ Proof of full vax req'd
⛔ Neg. COVID self-test req'd within 48 hrs prior to arrival
👩🔬 Regular onsite testing encouraged (& free)
😷 Masks expected indoors (& available onsite)
More info ➡️ https://t.co/zW1Lf1nnuk
Patients w/ brain tumors face barriers to enrollment in #clinicaltrials. Learn more + approaches to minimizing them in this paper by Drs. Eudocia Lee, Ross Camidge & @GautamMehtaMD. 🧠 https://t.co/oBT6Coqxdo #ASCOEdBook #CNStumors #btsm @CancerResrch
Congratulations to all distinguished recipients! #ASCO22 🎉🥳

Conquer Cancer, the ASCO Foundation on Twitter
“#ASCO22 is less than two weeks away, and we’ll be awarding more than $12 million in support to these and other incredible cancer research...
twitter.com
The Victoria’s Secret Global Fund for Women’s Cancers 2022 Career Development Awards, in Partnership with Pelotonia & AACR, are 2-year, $206,000 grants to support breast and gynecologic cancer research by female junior faculty scientists. Apply by June 28:
https://t.co/kMi1QETGF8
May is #OncologyNursingMonth. The AACR recognizes the vital role that oncology nurses play in improving the lives of patients with cancer. Oncology nurses are invited to join the AACR as Affiliate Members. Learn more:
https://t.co/3kDBaJMZtd
A virtual AACR forum will discuss how to accelerate the development of brain tumor therapies at 1 pm EDT on Thurs, May 26. Panelists include @Tsarmstrong01, Chetan Bettegowda, Andrew Kaczynski @KFILE, @michelle_monje, and @roelverhaak. Learn more:
https://t.co/jY8TwckEYm
@CD_AACR
Immune Evasion in Hodgkin and Non-Hodgkin Lymphomas:
Margaret A. Shipp, Scott J. Rodig, and Justin P. Kline will address this topic in a plenary at the Third AACR International Meeting on Advances in Malignant Lymphoma, June 23-26 in Boston:
https://t.co/Tr4jzS2LSZ
#AACRlymph22
Our first CMO @rschilsky will be honored w the Allen S. Lichter Visionary Leader Award at #ASCO22 for decades-long career advancing cancer research & empowering countless clinicians and researchers to improve outcomes for patients. 🎉 #ASCODailyNews

ASCO Honors Dr. Richard Schilsky for Inspiring and Empowering Clinicians to Address Unmet Needs in Cancer Care
Richard L. Schilsky, MD, FACP, FSCT, FASCO, professor emeritus at the University of Chicago, has been honored with the 2022 Allen Lichter Visionary Le...
fal.cn
The AACR Distinguished Lectureship in Breast Cancer Research recognizes outstanding science that has inspired or could inspire new perspectives on the etiology, diagnosis, treatment, or prevention of breast cancer. Nominate a colleague by June 30:
https://t.co/oQT7KucTcg
Looking at the role of more-intense therapy in prostate cancer, Dana-Farber's Alicia Morgans, MD, MPH (@CaPsurvivorship ) discusses with @medpagetoday going beyond androgen-deprivation therapy for patients with metastatic #prostatecancer.

Alicia Morgans, MD, on Going Beyond ADT for Metastatic Prostate Cancer
Androgen-deprivation therapy (ADT) is no longer the standard of care for patients with metastatic hormone-sensitive prostate cancer (mHSPC), outside o...
ms.spr.ly
Recent publications
Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers.
Nature. 2022
Detection of EGFR mutations in non-small cell lung cancer by droplet digital PCR
PLoS One. 2022
Announcements
We are proud of our alumni and we celebrate their successes! Read what Allison O’Connell and Kristin DePeaux say about their time at the Belfer.
Strategic alliances

Our strategic alliances drive research innovations and lead to improved therapies to benefit cancer patients
Donor highlight
Robert and Renée Belfer’s transformative cumulative Dana-Farber investment of more than $25 million launched the Robert A. and Renée E. Belfer Center for Applied Cancer Science. Their generosity enabled the Belfer Center to integrate its scientific teams, produce innovative cancer models, partner with industry leaders, and accelerate the development of revolutionary therapies to treat cancer. We are grateful for their vision and incredible support.
